CO6592030A2 - Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa - Google Patents
Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosaInfo
- Publication number
- CO6592030A2 CO6592030A2 CO12203213A CO12203213A CO6592030A2 CO 6592030 A2 CO6592030 A2 CO 6592030A2 CO 12203213 A CO12203213 A CO 12203213A CO 12203213 A CO12203213 A CO 12203213A CO 6592030 A2 CO6592030 A2 CO 6592030A2
- Authority
- CO
- Colombia
- Prior art keywords
- alzheimer
- disease
- treatment
- ventricular dilation
- dilation rate
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 230000010339 dilation Effects 0.000 title abstract 2
- 230000002861 ventricular Effects 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- High Energy & Nuclear Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Disabilities (AREA)
- Physiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere al uso de seguimiento por IRM de la tasa de dilatación ventricular como una medida objetiva con el fin de evaluar la progresión de la enfermedad en pacientes que sufren de Alzheimer y para el propósito de determinar la eficacia terapéutica de un régimen de tratamiento para los pacientes de Alzheimer. Los métodos para tratar la enfermedad de Alzheimer y el control de la eficacia terapéutica se proporcionan.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32373910P | 2010-04-13 | 2010-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6592030A2 true CO6592030A2 (es) | 2013-01-02 |
Family
ID=44761427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12203213A CO6592030A2 (es) | 2010-04-13 | 2012-11-13 | Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8066993B2 (es) |
| EP (1) | EP2451348A4 (es) |
| JP (2) | JP2013509985A (es) |
| KR (1) | KR20130114563A (es) |
| CN (1) | CN102946799A (es) |
| AR (1) | AR081534A1 (es) |
| AU (1) | AU2011240556B2 (es) |
| BR (1) | BR112012026224A2 (es) |
| CA (1) | CA2795651A1 (es) |
| CL (1) | CL2012002852A1 (es) |
| CO (1) | CO6592030A2 (es) |
| EA (1) | EA201291040A1 (es) |
| IL (1) | IL222245A0 (es) |
| MX (1) | MX2012011924A (es) |
| SG (1) | SG184820A1 (es) |
| TW (1) | TW201138807A (es) |
| WO (1) | WO2011130355A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090280114A1 (en) * | 2002-04-12 | 2009-11-12 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| EP2742855A1 (en) * | 2012-12-11 | 2014-06-18 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition |
| EP2994160B1 (en) * | 2013-05-06 | 2019-07-03 | Baxalta Incorporated | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
| CN106163548A (zh) * | 2014-02-08 | 2016-11-23 | 健泰科生物技术公司 | 治疗阿尔茨海默氏病的方法 |
| JP6548615B2 (ja) * | 2016-08-23 | 2019-07-24 | 富士フイルム株式会社 | 磁場歪み算出装置、方法およびプログラム |
| CN108830830A (zh) * | 2018-05-11 | 2018-11-16 | 深圳博脑医疗科技有限公司 | 一种脑萎缩程度的定量检测方法、检测装置及终端设备 |
| KR102276545B1 (ko) * | 2019-09-05 | 2021-07-15 | 고려대학교 산학협력단 | Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003064395A1 (ja) * | 2002-01-31 | 2005-05-26 | 国立精神・神経センター総長 | 神経変性疾患の予防又は治療剤 |
| EP1807119A2 (en) * | 2004-11-05 | 2007-07-18 | Wyeth a Corporation of the State of Delaware | Pet and magnetic resonance for screening alzheimer's disease therapeutics |
| WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| JP5555626B2 (ja) * | 2007-08-13 | 2014-07-23 | バクスター・インターナショナル・インコーポレイテッド | 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節 |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
-
2011
- 2011-04-13 WO PCT/US2011/032232 patent/WO2011130355A1/en active Application Filing
- 2011-04-13 AU AU2011240556A patent/AU2011240556B2/en not_active Ceased
- 2011-04-13 TW TW100112770A patent/TW201138807A/zh unknown
- 2011-04-13 US US13/086,285 patent/US8066993B2/en not_active Expired - Fee Related
- 2011-04-13 SG SG2012075479A patent/SG184820A1/en unknown
- 2011-04-13 EA EA201291040A patent/EA201291040A1/ru unknown
- 2011-04-13 JP JP2012539095A patent/JP2013509985A/ja active Pending
- 2011-04-13 MX MX2012011924A patent/MX2012011924A/es not_active Application Discontinuation
- 2011-04-13 KR KR1020127029420A patent/KR20130114563A/ko not_active Application Discontinuation
- 2011-04-13 BR BR112012026224A patent/BR112012026224A2/pt not_active IP Right Cessation
- 2011-04-13 EP EP11769496.8A patent/EP2451348A4/en not_active Withdrawn
- 2011-04-13 CA CA2795651A patent/CA2795651A1/en not_active Abandoned
- 2011-04-13 CN CN2011800191696A patent/CN102946799A/zh active Pending
- 2011-04-14 AR ARP110101285A patent/AR081534A1/es unknown
- 2011-10-17 US US13/274,886 patent/US8722042B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 JP JP2012115203A patent/JP2012210413A/ja active Pending
- 2012-10-09 IL IL222245A patent/IL222245A0/en unknown
- 2012-10-11 CL CL2012002852A patent/CL2012002852A1/es unknown
- 2012-11-13 CO CO12203213A patent/CO6592030A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20120071747A1 (en) | 2012-03-22 |
| IL222245A0 (en) | 2012-12-31 |
| JP2012210413A (ja) | 2012-11-01 |
| AU2011240556A1 (en) | 2012-04-19 |
| AU2011240556B2 (en) | 2012-06-21 |
| SG184820A1 (en) | 2012-11-29 |
| US20110251479A1 (en) | 2011-10-13 |
| CN102946799A (zh) | 2013-02-27 |
| EP2451348A4 (en) | 2013-07-31 |
| CA2795651A1 (en) | 2011-10-20 |
| AR081534A1 (es) | 2012-10-03 |
| TW201138807A (en) | 2011-11-16 |
| MX2012011924A (es) | 2013-03-05 |
| BR112012026224A2 (pt) | 2016-07-12 |
| WO2011130355A1 (en) | 2011-10-20 |
| US8722042B2 (en) | 2014-05-13 |
| JP2013509985A (ja) | 2013-03-21 |
| US8066993B2 (en) | 2011-11-29 |
| EA201291040A1 (ru) | 2013-04-30 |
| KR20130114563A (ko) | 2013-10-17 |
| CL2012002852A1 (es) | 2013-04-05 |
| EP2451348A1 (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6592030A2 (es) | Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa | |
| CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| HK1213192A1 (zh) | 用於在人類受試者中治療眼部疾病的方法和裝置 | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| EA201100335A8 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
| MX2013000675A (es) | Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer. | |
| MX2015001716A (es) | Niclosamida para el tratamiento de tumores solidos. | |
| CL2015002807A1 (es) | Terapia de combinación | |
| IL226975B (en) | Low-dose pioglitazone for the diagnosis and treatment of Alzheimer's disease | |
| EA201490230A1 (ru) | Применение меченых ингибиторов hsp90 | |
| MY164579A (en) | Safe and functional humanized antibodies | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| IN2015DN00450A (es) | ||
| BR112014025702A2 (pt) | compostos de tiofeno fotodinâmicos a base de metal e seus usos | |
| BR112015006705A8 (pt) | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático e usos destes | |
| BR112015027477A8 (pt) | bolus, seus usos, e kit | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| WO2015081283A3 (en) | Long non-coding rna as a diagnostic and therapeutic agent | |
| EP2734221A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM | |
| UA108975C2 (uk) | Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| BR112013025197A2 (pt) | métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer | |
| UA117809C2 (uk) | Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |